Colon Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Colon Cancer – Pipeline Review, H1 2017’, provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Colon Cancer

The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects

The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Colon Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

4P-Pharma SAS

Actinium Pharmaceuticals Inc

Adamed Sp z oo

Adgero Biopharmaceuticals Holdings Inc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Advanced Proteome Therapeutics Corp

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affimed GmbH

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

Ambrx Inc

Anavex Life Sciences Corp

AndroScience Corp

ANP Technologies Inc

Aphios Corp

Aposense Ltd

Aptose Biosciences Inc

Asana BioSciences LLC

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Bayer AG

BCN Biosciences LLC

BeyondSpring Pharmaceuticals Inc

BioCancell Ltd

Biogazelle NV

Blirt SA

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd

Celgene Corp

Celprogen Inc

Critical Outcome Technologies Inc

CrystalGenomics Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytune Pharma SAS

CZ BioMed Corp

Debiopharm International SA

DEKK-TEC Inc

Eli Lilly and Company

EntreChem SL

EnzymeBioSystems

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

GlaxoSmithKline Plc

GlycaNova Norway AS

GlycoMimetics Inc

Griffith University

Grunenthal GmbH

Halozyme Therapeutics Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Histogen Inc

HitGen LTD

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Idera Pharmaceuticals Inc

Immune Pharmaceuticals Inc

Immunomedics Inc

Immunotope Inc

Immupharma Plc

IMPACT Therapeutics Inc

Infinity Pharmaceuticals Inc

Innopharmax Inc

Intezyne Technologies Inc

Ironwood Pharmaceuticals Inc

Jasco Pharmaceuticals LLC

Jiangsu Kanion Pharmaceutical Co Ltd

JW Pharmaceutical Corp

Karyopharm Therapeutics Inc

Kineta Inc

Kyowa Hakko Kirin Co Ltd

Les Laboratoires Servier SAS

Lipocure Ltd

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lupin Ltd

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Meabco A/S

Medicenna Therapeutics Corp

Merus NV

Microlin Bio Inc

Moderna Therapeutics Inc

Molecular Targeting Technologies Inc

MolMed SpA

Mologen AG

Monopar Therapeutics LLC

Multimmune GmbH

Nektar Therapeutics

Northwest Biotherapeutics Inc

Novartis AG

Omeros Corp

OncoResponse Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orega Biotech SAS

OSE Immunotherapeutics

Panacea Pharmaceuticals Inc

Patrys Ltd

PharmaCyte Biotech Inc

Pharminox Ltd

Philogen SpA

Plexxikon Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

Qu Biologics Inc

Redx Pharma Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Sareum Holdings Plc

Sierra Oncology Inc

Sigma-Tau SpA

Sirnaomics Inc

Somantix BV

Sorrento Therapeutics Inc

Spring Bank Pharmaceuticals Inc

Starpharma Holdings Ltd

Sunshine Biopharma Inc

Synergys Biotherapeutics Inc

Systimmune Inc

Taiwan Liposome Company Ltd

Takis Srl

Transgene Biotek Ltd

TVAX Biomedical Inc

Tyg Oncology Ltd

Vaccibody AS

Vaccinogen Inc

Vault Pharma Inc

Vaxenta Biotechnologies

Vernalis Plc

VG Life Sciences Inc

Vivolux AB

Yakult Honsha Co Ltd

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Colon Cancer - Overview 8

Colon Cancer - Therapeutics Development 9

Colon Cancer - Therapeutics Assessment 42

Colon Cancer - Companies Involved in Therapeutics Development 64

Colon Cancer - Drug Profiles 136

Colon Cancer - Dormant Projects 692

Colon Cancer - Discontinued Products 703

Colon Cancer - Product Development Milestones 704

Appendix 714

List of Tables

List of Tables

Number of Products under Development for Colon Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Colon Cancer – Pipeline by 3-V Biosciences Inc, H1 2017

Colon Cancer – Pipeline by 4P-Pharma SAS, H1 2017

Colon Cancer – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Adamed Sp z oo, H1 2017

Colon Cancer – Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017

Colon Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Colon Cancer – Pipeline by Advanced Cancer Therapeutics LLC, H1 2017

Colon Cancer – Pipeline by Advanced Proteome Therapeutics Corp, H1 2017

Colon Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Colon Cancer – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Colon Cancer – Pipeline by Affimed GmbH, H1 2017

Colon Cancer – Pipeline by Agenus Inc, H1 2017

Colon Cancer – Pipeline by AGV Discovery SAS, H1 2017

Colon Cancer – Pipeline by AIMM Therapeutics BV, H1 2017

Colon Cancer – Pipeline by Ambrx Inc, H1 2017

Colon Cancer – Pipeline by Anavex Life Sciences Corp, H1 2017

Colon Cancer – Pipeline by AndroScience Corp, H1 2017

Colon Cancer – Pipeline by ANP Technologies Inc, H1 2017

Colon Cancer – Pipeline by Aphios Corp, H1 2017

Colon Cancer – Pipeline by Aposense Ltd, H1 2017

Colon Cancer – Pipeline by Aptose Biosciences Inc, H1 2017

Colon Cancer – Pipeline by Asana BioSciences LLC, H1 2017

Colon Cancer – Pipeline by AstraZeneca Plc, H1 2017

Colon Cancer – Pipeline by Atara Biotherapeutics Inc, H1 2017

Colon Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Colon Cancer – Pipeline by Bayer AG, H1 2017

Colon Cancer – Pipeline by BCN Biosciences LLC, H1 2017

Colon Cancer – Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by BioCancell Ltd, H1 2017

Colon Cancer – Pipeline by Biogazelle NV, H1 2017

Colon Cancer – Pipeline by Blirt SA, H1 2017

Colon Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Colon Cancer – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Colon Cancer – Pipeline by Celgene Corp, H1 2017

Colon Cancer – Pipeline by Celprogen Inc, H1 2017

Colon Cancer – Pipeline by Critical Outcome Technologies Inc, H1 2017

Colon Cancer – Pipeline by CrystalGenomics Inc, H1 2017

Colon Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by CytomX Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Cytune Pharma SAS, H1 2017

Colon Cancer – Pipeline by CZ BioMed Corp, H1 2017

Colon Cancer – Pipeline by Debiopharm International SA, H1 2017

Colon Cancer – Pipeline by DEKK-TEC Inc, H1 2017

Colon Cancer – Pipeline by Eli Lilly and Company, H1 2017

Colon Cancer – Pipeline by EntreChem SL, H1 2017

Colon Cancer – Pipeline by EnzymeBioSystems, H1 2017

Colon Cancer – Pipeline by F-star Biotechnology Ltd, H1 2017

Colon Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Colon Cancer – Pipeline by G1 Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Colon Cancer – Pipeline by GlycaNova Norway AS, H1 2017

Colon Cancer – Pipeline by GlycoMimetics Inc, H1 2017

Colon Cancer – Pipeline by Griffith University, H1 2017

Colon Cancer – Pipeline by Grunenthal GmbH, H1 2017

Colon Cancer – Pipeline by Halozyme Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Hamlet Pharma AB, H1 2017

Colon Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Colon Cancer – Pipeline by Histogen Inc, H1 2017

Colon Cancer – Pipeline by HitGen LTD, H1 2017

Colon Cancer – Pipeline by Horizon Pharma Plc, H1 2017

Colon Cancer – Pipeline by Hummingbird Bioscience Pte Ltd, H1 2017

Colon Cancer – Pipeline by Idera Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Immunomedics Inc, H1 2017

Colon Cancer – Pipeline by Immunotope Inc, H1 2017

Colon Cancer – Pipeline by Immupharma Plc, H1 2017

Colon Cancer – Pipeline by IMPACT Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Infinity Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Innopharmax Inc, H1 2017

Colon Cancer – Pipeline by Intezyne Technologies Inc, H1 2017

Colon Cancer – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Jasco Pharmaceuticals LLC, H1 2017

Colon Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Colon Cancer – Pipeline by JW Pharmaceutical Corp, H1 2017

Colon Cancer – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Kineta Inc, H1 2017

Colon Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Colon Cancer – Pipeline by Les Laboratoires Servier SAS, H1 2017

Colon Cancer – Pipeline by Lipocure Ltd, H1 2017

Colon Cancer – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Colon Cancer – Pipeline by Loxo Oncology Inc, H1 2017

Colon Cancer – Pipeline by Lupin Ltd, H1 2017

Colon Cancer – Pipeline by Lymphocyte Activation Technologies SA, H1 2017

Colon Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Colon Cancer – Pipeline by MacroGenics Inc, H1 2017

Colon Cancer – Pipeline by Mateon Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by MaxiVAX SA, H1 2017

Colon Cancer – Pipeline by Meabco A/S, H1 2017

Colon Cancer – Pipeline by Medicenna Therapeutics Corp, H1 2017

Colon Cancer – Pipeline by Merus NV, H1 2017

Colon Cancer – Pipeline by Microlin Bio Inc, H1 2017

Colon Cancer – Pipeline by Moderna Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Molecular Targeting Technologies Inc, H1 2017

Colon Cancer – Pipeline by MolMed SpA, H1 2017

Colon Cancer – Pipeline by Mologen AG, H1 2017

Colon Cancer – Pipeline by Monopar Therapeutics LLC, H1 2017

Colon Cancer – Pipeline by Multimmune GmbH, H1 2017

Colon Cancer – Pipeline by Nektar Therapeutics, H1 2017

Colon Cancer – Pipeline by Northwest Biotherapeutics Inc, H1 2017

Colon Cancer – Pipeline by Novartis AG, H1 2017

Colon Cancer – Pipeline by Omeros Corp, H1 2017

Colon Cancer – Pipeline by OncoResponse Inc, H1 2017

Colon Cancer – Pipeline by Oncovir Inc, H1 2017

Colon Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Colon Cancer – Pipeline by Orega Biotech SAS, H1 2017

Colon Cancer – Pipeline by OSE Immunotherapeutics, H1 2017

Colon Cancer – Pipeline by Panacea Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Patrys Ltd, H1 2017

Colon Cancer – Pipeline by PharmaCyte Biotech Inc, H1 2017

Colon Cancer – Pipeline by Pharminox Ltd, H1 2017

Colon Cancer – Pipeline by Philogen SpA, H1 2017

Colon Cancer – Pipeline by Plexxikon Inc, H1 2017

Colon Cancer – Pipeline by Provecs Medical GmbH, H1 2017

Colon Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Qu Biologics Inc, H1 2017

Colon Cancer – Pipeline by Redx Pharma Plc, H1 2017

Colon Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Rgenix Inc, H1 2017

Colon Cancer – Pipeline by Sareum Holdings Plc, H1 2017

Colon Cancer – Pipeline by Sierra Oncology Inc, H1 2017

Colon Cancer – Pipeline by Sigma-Tau SpA, H1 2017

Colon Cancer – Pipeline by Sirnaomics Inc, H1 2017

Colon Cancer – Pipeline by Somantix BV, H1 2017

Colon Cancer – Pipeline by Sorrento Therapeutics Inc, H1 2017

Colon Cancer – Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017

Colon Cancer – Pipeline by Starpharma Holdings Ltd, H1 2017

Colon Cancer – Pipeline by Sunshine Biopharma Inc, H1 2017

Colon Cancer – Pipeline by Synergys Biotherapeutics Inc, H1 2017

Colon Cancer – Pipeline by Systimmune Inc, H1 2017

Colon Cancer – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Colon Cancer – Pipeline by Takis Srl, H1 2017

Colon Cancer – Pipeline by Transgene Biotek Ltd, H1 2017

Colon Cancer – Pipeline by TVAX Biomedical Inc, H1 2017

Colon Cancer – Pipeline by Tyg Oncology Ltd, H1 2017

Colon Cancer – Pipeline by Vaccibody AS, H1 2017

Colon Cancer – Pipeline by Vaccinogen Inc, H1 2017

Colon Cancer – Pipeline by Vault Pharma Inc, H1 2017

Colon Cancer – Pipeline by Vaxenta Biotechnologies, H1 2017

Colon Cancer – Pipeline by Vernalis Plc, H1 2017

Colon Cancer – Pipeline by VG Life Sciences Inc, H1 2017

Colon Cancer – Pipeline by Vivolux AB, H1 2017

Colon Cancer – Pipeline by Yakult Honsha Co Ltd, H1 2017

Colon Cancer – Pipeline by ZIOPHARM Oncology Inc, H1 2017

Colon Cancer – Dormant Projects, H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..3), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..4), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..5), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..6), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..7), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..8), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..9), H1 2017

Colon Cancer – Dormant Projects, H1 2017 (Contd..10), H1 2017

Colon Cancer – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Colon Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports